Based on these results, we further explored the relationship between cuproptosis and HLA-DRA by treating ccRCC cells with different concentrations of elesclomol and Cu for 8, 16, and 24 h (Figure 5G–I). This evidence concerns the gene HLA-DRA and nonpapillary renal cell carcinoma.